We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Platelet Size Predicts Mortality in Patients with Sepsis

By LabMedica International staff writers
Posted on 26 Jul 2012
A new study suggests that the mean platelet volume (MPV) is an easily accessible prognostic marker of mortality in sepsis.

Researchers at Klinikum St. More...
Georg (Leipzig, Germany) conducted a study involving 191 patients (median age 72, 38% women) with documented sepsis. The researchers prospectively evaluated MPV at admission, at the onset of sepsis, at the diagnosis of sepsis, and during the course of the disease, as a marker for the prediction of outcomes. These data were compared with data from 56 patients (median age was 74, 45.5% women) with acute upper and lower gastrointestinal (GI) bleeding, who served as control subjects. Data on other standard laboratory biomarkers and clinical parameters were collected at the same time.

The results showed MPV on admission and at the onset of symptoms was strongly associated with death. Of 183 sepsis patients, 41 (21.5%) that died had a higher MPV than survivors (9.6 vs. 9.19 femtoliter (fL), respectively). At the time of positive blood cultures, those values had increased (11.2 vs. 9.7 fL).

Parameters of temperature, leukocyte count, lactate, procalcitonin, and C-reactive protein (CRP) values, on the other hand, were not at all predictive of outcome. The researchers then determined that the best predictor of death or survival was when they used an MPV discriminatory value of 8.7 fL. The study was presented as poster session at the 15th International Congress on Infectious Diseases, held during June 2012 in Bangkok (Thailand).

“This figure is at the high end of the normal range of platelet volumes, but is still highly predictive of poor outcome, namely death, in patients with sepsis,” said lead author and study presenter Thomas Grünewald, MD, PhD, head of the division of infectious diseases and tropical medicine. “We saw that patients with MPVs higher than 8.7 are much more prone — the odds ratio is 3.2 — to worse outcomes (for example, death) than patients with MPVs lower than 8.7.”

MPV is a machine-calculated measurement of the average size of platelets found in blood and is typically included in blood tests as part of the CBC. Since the average platelet size is larger when the body is producing increased numbers of platelets, the MPV test results can be used to make inferences about platelet production in bone marrow or platelet destruction problems. A typical range of platelet volumes is 9.7–12.8 fL, equivalent to spheres 2.65 to 2.9 µm in diameter.

Related Links:

Klinikum St. Georg





Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.